X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5807) 5807
Book Chapter (57) 57
Newspaper Article (15) 15
Magazine Article (6) 6
Newsletter (2) 2
Transcript (2) 2
Book / eBook (1) 1
Conference Proceeding (1) 1
Publication (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4809) 4809
female (1969) 1969
male (1961) 1961
risk factors (1902) 1902
anticoagulants (1828) 1828
anticoagulants - adverse effects (1565) 1565
anticoagulants - therapeutic use (1414) 1414
aged (1370) 1370
middle aged (1284) 1284
hematology (1254) 1254
rivaroxaban (1130) 1130
treatment outcome (1106) 1106
warfarin (1081) 1081
hemorrhage - chemically induced (1057) 1057
peripheral vascular disease (1038) 1038
anticoagulants - administration & dosage (1012) 1012
venous thromboembolism (986) 986
prevention (967) 967
administration, oral (937) 937
cardiac & cardiovascular systems (906) 906
thromboembolism (887) 887
thrombosis (875) 875
atrial fibrillation (866) 866
factor xa inhibitors (854) 854
pharmacology & pharmacy (803) 803
animals (799) 799
adult (798) 798
stroke (776) 776
dabigatran (745) 745
care and treatment (666) 666
atrial fibrillation - drug therapy (654) 654
medicine & public health (617) 617
factor xa inhibitors - adverse effects (616) 616
stroke - prevention & control (601) 601
aged, 80 and over (593) 593
molecular-weight heparin (578) 578
time factors (575) 575
drug therapy (564) 564
anticoagulation (548) 548
blood coagulation - drug effects (548) 548
analysis (547) 547
thrombin (539) 539
surgery (538) 538
health aspects (534) 534
apixaban (521) 521
atrial fibrillation - complications (520) 520
abridged index medicus (514) 514
heparin (509) 509
risk assessment (499) 499
risk (490) 490
bleeding (478) 478
mortality (473) 473
research (473) 473
deep-vein thrombosis (470) 470
factor xa inhibitor (467) 467
management (465) 465
factor xa inhibitors - therapeutic use (463) 463
enoxaparin (453) 453
patients (443) 443
safety (435) 435
risk-factors (429) 429
hemorrhage (428) 428
atrial-fibrillation (426) 426
cardiology (418) 418
medicine, general & internal (416) 416
therapy (412) 412
coagulation (410) 410
venous thromboembolism - prevention & control (407) 407
factor xa inhibitors - administration & dosage (400) 400
warfarin - adverse effects (387) 387
stroke - etiology (385) 385
double-blind (381) 381
dosage and administration (380) 380
complications and side effects (364) 364
anticoagulants - pharmacology (361) 361
pharmacokinetics (360) 360
retrospective studies (360) 360
dabigatran etexilate (354) 354
clinical trials (349) 349
dose-response relationship, drug (341) 341
thromboembolism - prevention & control (341) 341
fibrinolytic agents - therapeutic use (338) 338
internal medicine (336) 336
rivaroxaban - adverse effects (333) 333
warfarin - therapeutic use (331) 331
heparin - adverse effects (328) 328
thromboprophylaxis (327) 327
aspirin (326) 326
prospective studies (320) 320
antithrombotic therapy (314) 314
vitamin k - antagonists & inhibitors (311) 311
cardiac arrhythmia (308) 308
fibrinolytic agents - adverse effects (305) 305
oral anticoagulants (298) 298
review (295) 295
unfractionated heparin (295) 295
pyrazoles - adverse effects (293) 293
pyridones - adverse effects (292) 292
venous thromboembolism - drug therapy (284) 284
factor-xa inhibitor (276) 276
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5752) 5752
German (53) 53
French (24) 24
Spanish (22) 22
Japanese (17) 17
Russian (12) 12
Italian (9) 9
Polish (7) 7
Chinese (3) 3
Czech (3) 3
Danish (3) 3
Hungarian (3) 3
Dutch (2) 2
Norwegian (2) 2
Portuguese (2) 2
Swedish (2) 2
Slovenian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 25, pp. 2413 - 2424
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
Archives of Cardiovascular Diseases, ISSN 1875-2136, 2013, Volume 106, Issue 6-7, pp. 382 - 393
Summary Direct new oral anticoagulants (NOACs) – inhibitors of thrombin or factor Xa – are intended... 
Cardiovascular | Internal Medicine | Réversion | Hémorragie | Surgery | Reversal | Chirurgie | Anti-Xa | Bleeding | Anti-IIa | CARDIAC & CARDIOVASCULAR SYSTEMS | ASSAYS LABORATORY RECOMMENDATIONS | RIVAROXABAN | PHARMACODYNAMICS | COAGULATION ASSAYS | ATRIAL-FIBRILLATION | DABIGATRAN ETEXILATE | PHARMACOKINETICS | WARFARIN | PROTHROMBIN COMPLEX CONCENTRATE | Anti-lla | Perioperative Care | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Postoperative Hemorrhage - diagnosis | Postoperative Hemorrhage - chemically induced | Antithrombins - administration & dosage | Dabigatran | Drug Monitoring - methods | Rivaroxaban | Time Factors | Patient Safety | Benzimidazoles - adverse effects | Postoperative Hemorrhage - therapy | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Surgical Procedures, Operative - adverse effects | beta-Alanine - adverse effects | Drug Administration Schedule | Risk Assessment | Administration, Oral | Hemorrhage - therapy | Risk Factors | Emergencies | Treatment Outcome | Anticoagulants - adverse effects | Anticoagulants - blood | Hemorrhage - diagnosis | Coagulants - therapeutic use | Blood Coagulation - drug effects | Hemostatic Techniques | Antithrombins - adverse effects | Antithrombins - blood | Blood Coagulation Tests | Hemorrhage - chemically induced | Coagulants - adverse effects
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 11/2012, Volume 108, Issue 5, pp. 876 - 886
.... Rivaroxaban and apixaban (direct factor Xa inhibitors) and dabigatran etexilate (a direct thrombin inhibitor... 
Recommendations | rivaroxaban | practical management | anticoagulant | Consensus Paper | Rivaroxaban | Anticoagulant | Practical management | ENOXAPARIN | BAY-59-7939 | SAFETY | PREVENTION | PHARMACODYNAMICS | recommendations | VENOUS THROMBOEMBOLISM | ANTITHROMBOTIC AGENTS | PHARMACOKINETICS | ASSAYS | PERIPHERAL VASCULAR DISEASE | THROMBOPROPHYLAXIS | HEMATOLOGY | Thiophenes - therapeutic use | Anticoagulants - administration & dosage | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Male | Thiophenes - administration & dosage | Dabigatran | Warfarin - administration & dosage | Venous Thromboembolism - prevention & control | Benzimidazoles - administration & dosage | Arthroplasty, Replacement, Knee | Female | Venous Thrombosis - prevention & control | beta-Alanine - analogs & derivatives | Morpholines - adverse effects | Morpholines - therapeutic use | Blood Loss, Surgical - prevention & control | Stroke - prevention & control | Venous Thrombosis - drug therapy | Atrial Fibrillation - drug therapy | Morpholines - administration & dosage | beta-Alanine - administration & dosage | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Clinical Trials as Topic | Anticoagulants - adverse effects | Pregnancy | Practice Guidelines as Topic | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Medicin och hälsovetenskap | Klinisk medicin
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous thromboembolism after hip replacement, without a significant increase in major bleeding... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2019, Volume 380, Issue 14, pp. 1326 - 1335
Journal Article